89bio, Inc.
https://www.89bio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From 89bio, Inc.
Novo Nordisk Has Plans For Semaglutide In NASH Too
With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.
89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients
At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.
Akero Looks Ahead To Phase III In Cirrhotic NASH Despite Phase IIb Miss On Fibrosis
Already prepping Phase III trials of efruxifermin in pre-cirrhotic NASH patients, Akero says it will go ahead with Phase III plans in cirrhotic patients despite missing the fibrosis endpoint in a Phase IIb trial.
A Look Into The Future Of NASH
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- 89bio Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice